KNOXVILLE, TN, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1b/2 clinical trial of investigational cancer immunotherapy PV-10 (rose ...

Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today highlighted newly published independent preclinical research evaluating the effects of PV-10 in a clinically ...

Names Ed Pershing as Chief Executive Officer and Dominic Rodrigues as President KNOXVILLE, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) ...

NOOSAVILLE, Australia, July 22, 2025--(BUSINESS WIRE)--Provectus Algae (Provectus) announced today that it has raised US$10.1M in Series A financing and an additional US$2.5M in grant funding from the ...

NOOSAVILLE, Australia--(BUSINESS WIRE)--Provectus Algae (Provectus), an Australian synthetic biology company specializing in microalgal biomanufacturing technologies for the production of specialty ...

KNOXVILLE, TN, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on a formulation of the Company’s pharmaceutical-grade rose bengal against ...

Provectus Algae (Provectus) has announced that Steven F. Schnittger has joined the company as a cosmetics industry advisor. Schnittger is the former Vice-President of Global Fermentation and ...

Company plans to seek end-of-phase meeting with Australia’s Therapeutic Goods Administration in Q1 2021 KNOXVILLE, TN, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the ...

Provectus shares tumble after it refutes misleading claims in a blog. Find out what investors should really be paying attention to instead. Although we don't believe in timing the market or panicking ...

KNOXVILLE, TN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that data from the Company’s ongoing, multi-cohort, Phase 1b/2 study of the combination therapy of cancer ...

Provectus Pharmaceuticals, a biotech company developing oncology and dermatology drugs, has inked a $1 million investment from Chicago-based Lincoln Park Capital Fund. As part of the deal, Lincoln ...

Federal investigators accuse two former Provectus Biopharmaceuticals Inc. executives of defrauding investors of millions. A lawsuit filed Dec. 12 in Knoxville’s U.S. District Court accuses Provectus ...